Paul Zito
Internal Medicine · Austin, TXNPI 1396155966
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,827 of the $3,468 with a category attached, or 81.5%. It is spread thinly across 36 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 136 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$569
- AstraZeneca$474
- Daiichi Sankyo Inc.$234
- Novartis$183
- E.r. Squibb & Sons, L.L.C.$172
- Ipsen Biopharmaceuticals, Inc$159
- plus $2K from 30 others
Across 10 payments — averaging $14,211 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$142K
What the payments were for
- Food & beverage$2,82782%
- Education$64018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $569 |
| AstraZeneca | 9 | $474 |
| Daiichi Sankyo Inc. | 5 | $234 |
| Novartis | 9 | $183 |
| E.r. Squibb & Sons, L.L.C. | 10 | $172 |
| Ipsen Biopharmaceuticals, Inc | 8 | $159 |
| Intuitive Surgical | 2 | $143 |
| Caris MPI, Inc. | 2 | $141 |
| Blueprint Medicines Corporation | 1 | $122 |
| Tempus AI, Inc | 1 | $119 |
| AVEO Pharmaceuticals, Inc. | 1 | $119 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $119 |
| Astellas Pharma US Inc | 2 | $101 |
| Amgen | 5 | $93 |
| Sanofi | 4 | $71 |
| Eisai Inc. | 4 | $65 |
| Bayer | 3 | $57 |
| Lilly USA, LLC | 3 | $48 |
| Genentech USA, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $41 |
| Bristol Myers Squibb | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Genmab U.S., Inc. | 1 | $33 |
| Seagen Inc. | 2 | $31 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Incyte Corporation | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Gilead | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| GSK | 1 | $20 |
| Verastem, Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$235
- Enhertu$142
- MI CANCER SEEK$137
- Da Vinci Surgical System$130
- AYVAKIT$122
- XT CDX$119
- FOTIVDA$119
- IMBRUVICA$105
How this compares
$3,468 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 42 | $634,367 |
| RevlimidLenalidomide | 35 | $476,806 |
| InlytaAxitinib | 19 | $335,088 |
| TagrissoOsimertinib Mesylate | 21 | $334,221 |
| VonjoPacritinib Citrate | 13 | $327,048 |
| VerzenioAbemaciclib | 20 | $297,998 |
| CabometyxCabozantinib S-Malate | 12 | $292,567 |
| BosulifBosutinib | 14 | $270,520 |
| XtandiEnzalutamide | 12 | $165,973 |
| NubeqaDarolutamide | 11 | $147,334 |
| EliquisApixaban | 67 | $39,635 |
| Anastrozole | 349 | $9,897 |
| Exemestane | 19 | $7,078 |
| Fentanyl | 16 | $3,075 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 32 | $1,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Bosulif, Eliquis | $569 | $1,279,610142 claims |
| Bristol Myers SquibbRevlimid | $40 | $476,80635 claims |
| AstraZenecaTagrisso | $474 | $334,22121 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $48 | $298,24949 claims |
| Astellas Pharma US IncXtandi | $101 | $165,97312 claims |
| BayerNubeqa | $57 | $147,33411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Austin
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.